Table 5 Comparison of risk groups based on RPA model, N category and clinical stage.

From: Genetic variations in the PI3K-PTEN-AKT-mTOR pathway are associated with distant metastasis in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy

 

RPA model

N category

Clinical stage

Patients distributions

RPA1:43.3%

N0:10.5%

Stage I:5.2%

 

RPA2:14.1%

N1:46.9%

Stage II:20.2%

 

RPA3:33.4%

N2:29.6%

Stage III:31.8%

 

RPA4:9.2%

N3:13.0%

Stage IV:42.8%

5y-DMFS(%)

RPA1:93.7%

N0:95.5%

Stage I:100%

 

RPA2:88.3%

N1:91.7%

Stage II:88.6%

 

RPA3:81.2%

N2:79.8%

Stage III:86.1%

 

RPA4:62.7%

N3:70.6%

Stage IV:82.4%

P value

p < 0.001

p < 0.001

0.027

AIC

741.252

745.145

759.345

C-index

0.795

0.793

0.762

Back to article page